Test Price
2,800 AED✅ Home Collection Available
ARMC4 Gene Primary Ciliary Dyskinesia Type 23 Genetic Test at DNA Labs UAE – 2800 AED
Executive Summary & Core Metrics
Diagnostic Accuracy Guarantee: 99.9% sensitivity for pathogenic variants in the ARMC4 gene via ISO 9001:2015 accredited Next‑Generation Sequencing (NGS) workflow (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM by DHA‑licensed phlebotomists.
Clinical Guidance: Post‑test telephonic interpretation with a multidisciplinary team (ENT, Pulmonology, Clinical Genetics).
Insurance Billing: Direct verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This advanced NGS assay screens the entire coding region and exon‑intron boundaries of the ARMC4 gene to detect single nucleotide variants, small insertions/deletions, and copy number variations associated with primary ciliary dyskinesia type 23 (PCD23). The test replaces obsolete single‑gene methods, delivering comprehensive results in 3–4 weeks from whole blood, extracted DNA, or dried blood spot on an FTA card.
| Feature | DNA Labs UAE (NGS Panel) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision / Sensitivity | >99.9% (NGS with CNV detection and MLPA confirmation) | ~98% for point mutations; limited CNV detection |
| Methodology | Next‑Generation Sequencing (Illumina® platform) + bioinformatic pipeline aligned to DHA/MOHAP standards | Sanger sequencing of individual exons (time‑consuming iterative process) |
| Turnaround Speed | 3–4 weeks | 8–12 weeks (if full gene coverage required) |
| Sample Types Accepted | Whole Blood (EDTA), Extracted DNA, Dried Blood Spot (FTA Card) | Whole Blood only |
| Price | 2800 AED (inclusive of genetic counselling) | Variable; often higher cumulative cost for full gene coverage |
Physician Insight & Safety Protocols
“Primary ciliary dyskinesia is a complex condition that affects multiple organ systems. This targeted genetic test provides clarity for families and enables personalised management strategies, especially when combined with clinical and radiological assessments. Our team ensures each result is explained with compassion and evidence‑based guidance.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory: Do Not Discontinue Therapy Without Physician Consultation
🛑 Medication Warning
Do not discontinue any prescribed medication (e.g., mucolytics, bronchodilators, or prophylactic antibiotics) without consulting your managing physician. Stopping therapy abruptly can lead to acute respiratory deterioration.
Safety Exclusion Criteria & Emergency Red Flags
⚠️ Exclusion Criteria
- Patients with acute febrile illness or haemodynamic instability – postpone blood draw until clinically stable.
- Inability to provide informed consent (guardian consent mandatory for minors).
- Known severe bleeding diathesis – discuss with laboratory physician prior to venipuncture.
🚨 Seek Immediate Emergency Care If You Experience
- Sudden severe shortness of breath or cyanosis (bluish lips/fingertips).
- Sharp chest pain that worsens with breathing.
- High fever (>39°C) unresponsive to antipyretics.
Patient FAQ & Clinical Guidance
1. Why do I need this ARMC4 gene test and what does it tell my doctor?
Direct Answer: This test identifies pathogenic variants in the ARMC4 gene that cause primary ciliary dyskinesia type 23, confirming diagnosis and guiding personalised treatment plans for chronic lung, sinus, and fertility issues.
2. How accurate is the NGS test, and can I trust home collection?
Direct Answer: The test achieves over 99.9% diagnostic sensitivity for all ARMC4 mutations, and our DHA‑licensed phlebotomy team maintains strict cold‑chain certification to ensure sample integrity from your doorstep.
3. What do I do if my test result is positive for a pathogenic variant?
Direct Answer: A positive result mandates immediate multidisciplinary consultation (ENT, pulmonology, genetics) to establish a proactive health surveillance plan and discuss familial implications, fully supported by our genetic counselling team.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic data is handled in compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Patient Safety & Consent: Clinical testing procedures and patient consent adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your rights and confidentiality are fully protected throughout the testing process.
Clinical & Logistical Metadata
| Test Name | ARMC4 Gene Primary Ciliary Dyskinesia Type 23 Genetic Test |
| Price (AED) | 2800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, Dried Blood Spot (FTA Card) |
| Methodology Used | Next‑Generation Sequencing (NGS) on Illumina® platform |
| ICD-10-CM Code | Q34.8 (Primary ciliary dyskinesia) |
| LOINC Code | 21636-5 (Gene mutations identified in Blood or Tissue by Molecular genetics method Interpretation) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians